RT Journal Article
SR Electronic
T1 Cell type-specific immune dysregulation in severely ill COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.23.20161182
DO 10.1101/2020.07.23.20161182
A1 Yao, Changfu
A1 Bora, Stephanie A
A1 Parimon, Tanyalak
A1 Zaman, Tanzira
A1 Friedman, Oren A
A1 Palatinus, Joseph A
A1 Surapaneni, Nirmala S
A1 Matusov, Yuri P
A1 Chiang, Giuliana Cerro
A1 Kassar, Alexander G
A1 Patel, Nayan
A1 Green, Chelsi ER
A1 Aziz, Adam W
A1 Suri, Harshpreet
A1 Suda, Jo
A1 Lopez, Andres A
A1 Martins, Gislaine A
A1 Stripp, Barry R
A1 Gharib, Sina A
A1 Goodridge, Helen S
A1 Chen, Peter
YR 2020
UL http://medrxiv.org/content/early/2020/07/24/2020.07.23.20161182.abstract
AB Coronavirus disease 2019 (COVID-19) has quickly become the most serious pandemic since the 1918 flu pandemic. In extreme situations, patients develop a dysregulated inflammatory lung injury called acute respiratory distress syndrome (ARDS) that causes progressive respiratory failure requiring mechanical ventilatory support. Recent studies have demonstrated immunologic dysfunction in severely ill COVID-19 patients. To further delineate the dysregulated immune response driving more severe clinical course from SARS-CoV-2 infection, we used single-cell RNA sequencing (scRNAseq) to analyze the transcriptome of peripheral blood mononuclear cells (PBMC) from hospitalized COVID-19 patients having mild disease (n = 5), developing ARDS (n = 6), and recovering from ARDS (n = 6). Our data demonstrated an overwhelming inflammatory response with select immunodeficiencies within various immune populations in ARDS patients. Specifically, their monocytes had defects in antigen presentation and deficiencies in interferon responsiveness that contrasted the higher interferon signals in lymphocytes. Furthermore, cytotoxic activity was suppressed in both NK and CD8 lymphocytes whereas B cell activation was deficient, which is consistent with the delayed viral clearance in severely ill COVID-19 patients. Finally, we identified altered signaling pathways in the severe group that suggests immunosenescence and immunometabolic changes could be contributing to the dysfunctional immune response. Our study demonstrates that COVID-19 patients with ARDS have an immunologically distinct response when compared to those with a more innocuous disease course and show a state of immune imbalance in which deficiencies in both the innate and adaptive immune response may be contributing to a more severe disease course in COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by funding by the Parker B. Francis Foundation Fellowship (CY), Plum Foundation Funding (PC), Erwin Rautenberg Foundation Fellowship (TP), UCLA CTSI KL2 (TP), and NIH grants T32HL134637 (SAB, JAP), R01AI134987 (HSG), AI137111 (SAG), and R01HL137076 (PC).  No external payment or services were received from a third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CSMC IRB STUDY00000602 IRB PRO00043021All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the sequencing data along with their associated metadata and accession code will be made available upon peer-reviewed publication.